LivaNova PLC, a top medical technology company listed on Nasdaq as LIVN, has started making its Essenz Perfusion System available in China. This country is LivaNova’s second-largest market for heart-lung machines after the United States. The system, which recently got approval from China’s National Medical Products Administration, provides a more personalized way of perfusion using data insights. It’s meant to help improve how surgeries are done and lead to better results for patients during complicated heart-lung bypass operations.
Health Technology Insights: Vital User Count Surges Past 5-Million Patients, Expected to Triple by 2026
China is dealing with a big problem related to heart and blood vessel diseases, which affect about 330 million people. More than 700 hospitals in the country are set up to perform heart surgeries, and it’s expected that over 185,000 adult and 23,500 pediatric extracorporeal circulation procedures will be done in 2025 alone. This shows a growing need for advanced medical tech like the Essenz system.
Stephen Robins, who is a Chief Perfusionist at The Royal Wolverhampton NHS Trust in the UK and helped design the Essenz system, spoke about the system during launch events in China. He said, “LivaNova’s Essenz technology builds on the trusted safety and reliability of its earlier heart-lung machines. It gives perfusionists and surgeons better ergonomics, real-time data, and more control. The system supports complex surgical techniques and provides clear data for the surgical team, which is very important during operations.”
Health Technology Insights: Citizen Health Raises $30 Million to Build AI for Patient Advocacy
The Essenz Perfusion System is already in use in several countries, including the United States, Europe, Canada, Australia, Japan, and the UAE. Since it was first introduced in February 2023, it has been used to treat over 100,000 patients around the world. The system was created with input from more than 300 perfusionists globally, making sure it fits the needs of surgical teams while keeping patient safety and managing risks as top priorities.
Franco Poletti, LivaNova’s President of Cardiopulmonary, highlighted the company’s long relationship with Chinese medical professionals. “We’ve worked closely with top experts in China to develop extracorporeal circulation technology. Bringing Essenz to China is an important step that gives perfusionists and surgeons better tools for safer procedures, improving patient outcomes and raising the standard of care in the region,” he said.
The Essenz Perfusion System includes several parts such as the advanced Essenz heart-lung machine, an easy-to-use interface with real-time data through the Essenz Patient Monitor, and a highly accurate Essenz In-Line Blood Monitor. The system’s cockpit and patient monitor work separately but are connected, allowing each pump to be controlled independently for more precision and flexibility during surgeries.
Health Technology Insights: Nanosonics Launches Latest Innovation for High-Level Disinfection of Ultrasound Probes
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
